UY37594A - IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY - Google Patents

IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY

Info

Publication number
UY37594A
UY37594A UY0001037594A UY37594A UY37594A UY 37594 A UY37594 A UY 37594A UY 0001037594 A UY0001037594 A UY 0001037594A UY 37594 A UY37594 A UY 37594A UY 37594 A UY37594 A UY 37594A
Authority
UY
Uruguay
Prior art keywords
biomarcator
preach
immune
cancer immunotherapy
clinical effect
Prior art date
Application number
UY0001037594A
Other languages
Spanish (es)
Inventor
Hiroshi Kagamu
Original Assignee
Univ Saitama Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saitama Medical filed Critical Univ Saitama Medical
Publication of UY37594A publication Critical patent/UY37594A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a la predicción de la capacidad de respuesta a inmunoterapia del cáncer de un sujeto a base de la composición de células T del sujeto y un método terapéutico que usa inmunoterapia del cáncer en base a la predicción. La presente invención también proporciona un método para mejorar o mantener la capacidad de respuesta a inmunoterapia del cáncer de un sujeto.The present invention relates to the prediction of the immunotherapy response capacity of a subject's cancer based on the subject's T-cell composition and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining the immunotherapy responsiveness of a subject's cancer.

UY0001037594A 2017-02-07 2018-02-06 IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY UY37594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017020685 2017-02-07
JP2017110069 2017-06-02

Publications (1)

Publication Number Publication Date
UY37594A true UY37594A (en) 2018-08-31

Family

ID=61527481

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037594A UY37594A (en) 2017-02-07 2018-02-06 IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY

Country Status (13)

Country Link
US (3) US11293924B2 (en)
EP (2) EP3580569B1 (en)
JP (4) JP6664684B1 (en)
KR (2) KR102617574B1 (en)
CN (2) CN116712458A (en)
AU (1) AU2018218844B2 (en)
CA (1) CA3052027A1 (en)
IL (1) IL268524A (en)
MX (1) MX2019009386A (en)
SG (1) SG11201907102XA (en)
TW (2) TW202323820A (en)
UY (1) UY37594A (en)
WO (1) WO2018147291A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712458A (en) 2017-02-07 2023-09-08 学校法人埼玉医科大学 Immunological biomarkers for predicting clinical outcome of cancer immunotherapy
CN111344568B (en) * 2017-09-12 2024-05-28 免疫特征私人有限公司 Predicting response to immunotherapy
EP3876955A4 (en) * 2018-11-09 2022-08-24 Pierian Biosciences, LLC Methods and compositions for determining the composition of a tumor microenvironment
US20220096552A1 (en) 2019-02-20 2022-03-31 Saitama Medical University Method and composition for predicting long-term survival in cancer immunotherapy
CN113747919A (en) * 2019-02-20 2021-12-03 学校法人埼玉医科大学 Peripheral blood biomarkers for assessing anti-tumor immune effects obtained by radiation therapy
US20220178926A1 (en) * 2019-04-10 2022-06-09 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
JP6796737B1 (en) * 2020-06-02 2020-12-09 振武 曽 Multi-item automatic blood cell counter
EP4212174A4 (en) 2020-09-08 2024-09-11 Univ Saitama Medical Biomarker for predicting response to cancer treatment
EP4219738A1 (en) * 2020-09-25 2023-08-02 Suzhou Ersheng Biopharmaceutical Co., Ltd Detection method for tumor-specific t cells
CN112114129A (en) * 2020-09-25 2020-12-22 苏州大学 Method for detecting tumor specific T cells
WO2022215843A1 (en) * 2021-04-06 2022-10-13 (주)에스엠티바이오 Method for predicting therapeutic response of cancer patient to anticancer immunotherapy using natural killer cells
WO2023083924A1 (en) * 2021-11-10 2023-05-19 Institut Gustave Roussy Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy
CN114354931B (en) * 2021-12-14 2023-03-14 南方医科大学南方医院 Application of splenomegaly in determining curative effect of tumor patient immune checkpoint inhibitor treatment
US12013857B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Identifying hot items in a distributed storage system
US12013816B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Querying metadata in a storage system
WO2023230548A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024185887A1 (en) * 2023-03-08 2024-09-12 イミュニティリサーチ株式会社 System, method, and program for specifying cell population

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP2006280307A (en) * 2005-04-01 2006-10-19 Kyoto Univ Method for producing controllable t cell
ATE483470T1 (en) * 2005-12-21 2010-10-15 Sentoclone Ab METHOD FOR EXPANSION OF TUMOR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH CANCER
EP2173438A2 (en) * 2007-07-13 2010-04-14 Genentech, Inc. Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
WO2009062001A1 (en) 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20120088678A1 (en) * 2010-09-08 2012-04-12 Sanford-Burnham Medical Research Institute Method for prediction of response to rheumatoid arthritis therapeutics
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2012279225A1 (en) * 2011-07-01 2014-01-16 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
CN104769431A (en) * 2012-09-04 2015-07-08 国立大学法人新潟大学 Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
CN109793893B (en) 2012-09-07 2023-05-26 达特茅斯大学理事会 VISTA modulators for diagnosis and treatment of cancer
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
US20150118247A1 (en) 2013-10-25 2015-04-30 Nodality, Inc. Methods and compositions for immunomodulation
MX2017004007A (en) 2014-09-28 2018-05-07 Univ California Modulation of stimulatory and non-stimulatory myeloid cells.
DK3285809T3 (en) * 2015-04-20 2019-11-18 Effector Therapeutics Inc INHIBITORS OF IMMUNCTION POINT MODULATORS FOR USE IN TREATMENT OF CANCER AND INFECTIONS.
WO2017004192A1 (en) * 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
EP3417293A1 (en) 2016-02-18 2018-12-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
CN110461342A (en) 2017-02-06 2019-11-15 诺华股份有限公司 The method for predicting the reaction to immunotherapy
CN116712458A (en) 2017-02-07 2023-09-08 学校法人埼玉医科大学 Immunological biomarkers for predicting clinical outcome of cancer immunotherapy
US20200393469A1 (en) 2017-05-16 2020-12-17 Kurume University Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent

Also Published As

Publication number Publication date
EP3580569A1 (en) 2019-12-18
EP3580569B1 (en) 2022-03-09
AU2018218844A1 (en) 2019-09-19
JP2024023862A (en) 2024-02-21
MX2019009386A (en) 2019-11-05
JP2020512530A (en) 2020-04-23
CN110446928A (en) 2019-11-12
TW201833551A (en) 2018-09-16
KR102617574B1 (en) 2023-12-22
EP4039260A1 (en) 2022-08-10
SG11201907102XA (en) 2019-08-27
TWI795386B (en) 2023-03-11
US11293924B2 (en) 2022-04-05
KR20230017355A (en) 2023-02-03
AU2018218844B2 (en) 2024-08-01
IL268524A (en) 2019-09-26
KR102490278B1 (en) 2023-01-18
CA3052027A1 (en) 2018-08-16
KR20190112027A (en) 2019-10-02
JP2022105066A (en) 2022-07-12
US20220178933A1 (en) 2022-06-09
TW202323820A (en) 2023-06-16
US20230349909A1 (en) 2023-11-02
JP2020073924A (en) 2020-05-14
JP6664684B1 (en) 2020-03-13
WO2018147291A1 (en) 2018-08-16
EP4039260B1 (en) 2024-04-17
CN116712458A (en) 2023-09-08
US20200025768A1 (en) 2020-01-23
CN110446928B (en) 2023-06-20
JP7067804B2 (en) 2022-05-16

Similar Documents

Publication Publication Date Title
UY37594A (en) IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY
CY1125260T1 (en) TIGIT COMMITMENT FACTORS AND THEIR USES
CL2021000343A1 (en) Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)
CL2018001512A1 (en) Humanized anti-CD73 antibodies.
EA201992131A1 (en) HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
BR112018015485A2 (en) fabs-in-tandem immunoglobulin and its uses
CO2020014345A2 (en) Gucy2c-specific antibodies and their uses
ECSP19015192A (en) COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
CL2017000278A1 (en) Bispecific t-cell activating antigen binding molecules
TWD189788S (en) Shoe
BR112016030670A2 (en) "immunocytokine"
CO2017004932A2 (en) Methods for selecting and donor t cell line for adoptive cell therapy
BR112017001242A2 (en) cancer treatment using a cd33 chimeric antigen receptor
BR112016015140A2 (en) tandem-fab immunoglobulin and its uses
EA201790405A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS
EA201692477A1 (en) COMPOSITIONS AND METHODS OF APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
BR112017009671A2 (en) ezh2 inhibitors and uses of these
BR112016028891A2 (en) seed train processes and uses
AR104664A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES AGAINST CADHERINE 6 (ANTI-CDH6)
BR112016012860A2 (en) BIARYL COMPOUNDS USEFUL IN THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
BR112017012381A2 (en) immunotherapy for angiogenic disease
CL2018000597A1 (en) Methods to treat inflammatory diseases
CO2018012497A2 (en) Interferon beta antibodies and uses thereof
BR112018002382A2 (en) novel human anti-gvpi antibodies and their uses

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204